Top X Biologic Medicamenta in Civitatibus Foederatis Americae

by Kathlyn Stone

Tractatur haec medicamenta Mutans exitus incerti sunt via

Medicinae ex moleculis sunt universa Biologics fabricari, et viventem per microorganisms, plantis, vel animalis amet. Multi biologics non produci per DNA recombinante technology. Sunt interdum relatum ut ut Class Biopharmaceuticals aut medicaménta utíliter.

Biologics qui novas res in treatment multorum gravis et morbi cronici et nudged traditional parva moleculo-medica de vertice venditio foramina. Rheumatoid arthritis quidam carcinomata, diabetes sunt plurima genera biologic dedicavit. Biologics mutantur in via medici communis conditionibus hominum est, quod contriverim annis.

Buy Biologics

Medicinae ex oeconomiae plurimi summatim chemicals biologics magis intricatae amet debitam vestibulum elit. Excelsum prae pecunia requiratur magna generis medicamenta versionibus biologic nominatim recensentur infra decem. Pharmaceutical turmas in pluribus non lobbying ius ex genere efficere versions. Sed quia tam facile efficere, ut sunt fere de tam facultatem ad fabricabimus generics, et fideliter faciam confidenter.

Top X Biologics

Et decem venenum ut infra enumerantur omnes vehementer exceditur a financial definition of a "blockbuster" generatae autem quod dicit quod medicamento Sales magis quam $ I billion in anno.

In MMXV, biologics coepit adversus competition a biosimilars aut biogenerics, quod erat developed per Rituximab IDEC, tecta sub nomine IDEC C2B8. ^[I] US patentibus erat edita in MCMXCVIII defecit in patentibus 2015. Humira perdidit suum praesidium per MMXVI et in custodiis Remicade perdetur MMXVIII.

Et infra figuras sint ultima dies available pro sulum uber obtulerunt.

I Humira

Anti-inflammatione medicamento quod est non optimum-vendere Humira biologic; esset optimum-vendere medicamento worldwide, cujuscumque classis.

Indicia: Rheumatoid arthritis, plaque LEPRA, Crohn scriptor morbus, ulcerative COLITIS, ankylosing spondylitis, psoriatic arthritis, arthritis polyarticular Iuvenalibus idiopathica

Manufacturer: AbbVie, et Laboratories nent-off Cicero

Global Sales in MMXV: $ billion XIV

Buy nomen Adalimumab

Launch date, MMII

II Remicade

Remicade erat developed per Centocor Ortho Biotech principio, et nunc Biotech Janssen, Johnson & Johnson est subsidiarium.

Indicia: Rheumatoid arthritis, Crohn scriptor morbo, ankylosing spondylitis, psoriatic arthritis, plaque LEPRA, ulcerative COLITIS

Manufacturer: Johnson & Johnson / Merck Belize & Co.

Global Sales in MMXV: $ 5.78 billion

Buy nomen Infliximab

Launch date, MCMXCVIII

III Rituxan

Rituxan (rituximab) erat developed per IDEC, tecta sub nomine IDEC C2B8. Rituxan est currently co-venalicium in Civitatibus Foederatis Americae per Biogen Idec et subsidiary Genentech Rupe.

Indication: Non Hodgkins lymphoma, perpetuas lymphocytic leukemia, rheumatoid arthritis

Manufacturer: Rupe

Global Sales in MMXV: $ 7.32 billion

Buy nomen Rituximab

Launch date, MCMXCVII

IV Enbrel

Etanercept erat developed per inquisitores a Immunex. Quod pharmacum est hodie co-venales apud Americae Septentrionalis et Amgen a Pfizer per Takeda Pharma Wyeth in Japan et in reliquis mundi.

Indication: Rheumatoid arthritis, plaque LEPRA, psoriatic arthritis

Manufacturer: Pfizer / Amgen

Global Sales, in MMXVI: $ billion XXIII

Buy nomen Etanercept

Launch date, MCMXCVIII

V Lantus

Fuerat developed Lantus ad Sanofi-Aventis est biologica investigationis centrum, Höchst in Frankfurt, Germany.

Indication: DIABETES

Manufacturer: laboratorium Sanofi

Global Sales in MMXV: $ 6.98 billion

Buy nomen insulin glargine [rDNA originem] iniectio

Launch date, MM

VI avastin

Cum launched in MMIV, Genentech est avastin esset unus ex maxime pretiosa medicinae in foro, per $ 4,400 in mense pretium.

Indication: pectore in colorectal, renibus, non-parva-cell rege, glioblastoma, ovarian cancer

Manufacturer: Rupe

Global Sales in MMXV: $ 6.95 billion

Buy nomen Bevacizumab

Launch date, MMIV

VII Herceptin

Herceptin erat developed per Genentech nunc de Rupe subsidiary et Californa University of-Los Angeles, Expono Comprehensive Cancer Center.

Tumor, pectus cancer HER2 +

Manufacturer: Rupe

Global Sales in MMXV: $ 6.59 billion

Buy nomen trastuzumab

Launch date, MCMXCVIII

VIII Neulasta

Indication: Neutropenia ad cancer chemotherapy

Manufacturer: Amgen

Global Sales, in MMXVI: $ 4.6 billion

Buy nomen Pegfilgrastim

Launch date, MMII

IX Lucentis

Developed by Genentech, ranibizumab, et injectable, per Genentech est venales in Civitatibus Foederatis Americae et foris US laboratorium Novartis

Indication: Age-related macular degeneratum

Manufacturer: Rupe laboratorium Novartis

Global Sales in MMXV: $ 4,2 billion

Buy nomen Ranibizumab

Launch date, MMVI

X Avonex

Avonex est venales in Civitatibus Foederatis Americae per Biogen Idec et Merck sub notam nomen Rebif.

Engineering de Gemany Fraunhofer interfacial ad Institutum Biotechnology IGB quod Company et cloned CinnaGen Interferón beta-1a Cum MMVI, et venundati sunt ut ad medicamento CinnoVex a biosimilar in Iran.

Indication: duros nequeunt movere lumbos Tullius (MS)

Manufacturer: Biogen Idec

Global Sales in MMXIV: $ III billion

Buy nomen Interferón beta-1a

Launch date, MCMXCVI

Promissum biologics in in pipeline:

Sunt plura biologic medicamentum ex horizon, comprehendo medicinae tractare melanoma et aliis carcinomata sua. Laboratorium Sanofi et Regeneronhave partnered Alirocumab ut develop a Klon hypercholesterolemia tractandi. Janssen accepit FDA has "breakthrough" Lorem progressio est vocabulum ejus de myeloma multa curatio, Daratumumab est, Klon. Lorem accepisse vocabulum breakthrough Merck etiam per FDA-MMMCDLXXV MK, a Klon: melanoma animo pro provectus et aliis carcinomata sua.

Buy Biologics

Top X Biologics

I Humira

II Remicade

III Rituxan

IV Enbrel

V Lantus

VI avastin

VII Herceptin

VIII Neulasta

IX Lucentis

X Avonex

Promissum biologics in in pipeline:

Related Content

Fresh articles

Intresting articles